Oct 04th 2012 - Edison Investment Research today published a report on Allocate Software (ALL.L, LSE:ALL, LON:ALL) entitled "Slow Approval Cycles Bite". In summary, the report says:
Allocate’s Q1 licensing weakness continued, with decision paralysis within the NHS. Growth of subscription sales, particularly HealthRoster Cloud, should improve earnings visibility over time, but is not enough to offset the licensing shortfall in the short term, with our forecast EPS moving back by 18% for 2013 and 2014.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »